Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Washington hospital open since 1887 pauses heart transplant program due to vacancies
No other heart or transplant services at the nonprofit hospital should be impacted by this temporary shift in care.
Boston Scientific partners with Epic on data integration
The collaboration allows providers to order diagnostic tests and then receive results directly in Epic.
Semaglutide, other obesity drugs show potential to treat nondiabetic stroke
Much more research is still required, but a new meta-analysis in Stroke suggests these medications may provide valuable stroke prevention.
‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations
The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.
Beta-blockers do not benefit heart attack patients with a normal LVEF
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

Washington hospital open since 1887 pauses heart transplant program due to vacancies

No other heart or transplant services at the nonprofit hospital should be impacted by this temporary shift in care.

Boston Scientific partners with Epic on data integration

The collaboration allows providers to order diagnostic tests and then receive results directly in Epic.

Semaglutide, other obesity drugs show potential to treat nondiabetic stroke

Much more research is still required, but a new meta-analysis in Stroke suggests these medications may provide valuable stroke prevention.

‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations

The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.

Beta-blockers do not benefit heart attack patients with a normal LVEF

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Oral heart failure drug receives FDA’s fast track designation

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

FDA clears new ‘smart shirt’ for real-time cardiopulmonary monitoring

According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials.